Senti Biosciences Holdings Inc(SNTI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 5:17 AM ET (Korea 11/2 19:17)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.77 | Insider Own | - | Shs Outstand | 31.1M | Perf Week | -12.37% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 31.1M | Perf Month | -49.11% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 11.31% | Short Float | 1.37% | Perf Quarter | -55.39% |
| Income | -0.05B | P/S | 85.72 | EPS this Y | - | Inst Trans | 0.58% | Short Ratio | 0.12 | Perf Half Y | -83.81% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -97.52% | Short Interest | 0.43M | Perf YTD | -84.13% |
| Book/sh | -0.11 | P/C | 0.8 | EPS past 3/5Y | 50.33% 65.37% | ROE | -466.46% | 52W High | -94.27% ($2.88) | Perf Year | -92.21% |
| Cash/sh | 0.21 | P/FCF | - | Sales past 3/5Y | -82.75% -70.12% | ROIC | -530.66% | 52W Low | 5.83% ($0.16) | Perf 3Y | -94.12% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 80.28% | Gross Margin | -5630.91% | Volatility(W/M) | 21.73% 12.85% | Perf 5Y | -99.84% |
| Dividend TTM | - | EV/Sales | 315.22 | Sales Y/Y TTM | - | Oper. Margin | -102761.82% | ATR (14) | 0.03 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.83 | EPS Q/Q | 27.53% | Profit Margin | -90116.36% | RSI (14) | 29.9 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.83 | Sales Q/Q | - | SMA20 | -33.22% ($0.25) | Beta | 2.25 | Target Price | $15 |
| Payout | - | Debt/Eq | - | Earnings | 2026/08/18 | SMA50 | -44.81% ($0.31) | Rel Volume | 0.46 | Prev Close | $0.22 |
| Employees | 39 | LT Debt/Eq | - | EPS/Sales Surpr. | 61.11% - | SMA200 | -77.21% ($0.75) | Avg Volume(3M) | 3.46M | Price | $0.17 |
| IPO | 2021/5/26 | Option/Short | No/Yes | Trades | 1700 | Volume | 1,600,677 | Change | -23.92% |
🧫 Senti Biosciences () is a clinical-stage biotech that applies synthetic biology-based "logic gate" design to CAR-NK cell therapy. Its lead candidate, SENTI-202, is an off-the-shelf CAR-NK for acute myeloid leukemia (AML) and has received FDA Orphan Drug and RMAT designations.
Over the past 1 year, on the lower side
94% below its 1-year high.
Traded less than usual. That is 46% of its average volume.
SNTI has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $8,572. Peers typically go for $1,010.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #541 of 597 in the industry
Based on market cap of $5M.
LGVN#539 Longeveron Inc $5M PER - 
PCSA#540 Processa Pharmaceuticals Inc $5M PER - SNTI#541 Senti Biosciences Holdings Inc $5M PER - 
PULM#542 Pulmatrix Inc $5M PER - 
IMNN#543 Imunon Inc $5M PER - 
FAQ
What kind of company is SNTI?
SNTI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SNTI?
The market cap of SNTI is approximately $5M, ranking 5,611 within its sector.
What is the 52-week high and low for SNTI?
SNTI has recorded a 52-week high of $2.88 and a low of $0.16.
